Should lung cancer patients choose anlotinib or cabozantinib?

For lung cancer patients, the choice between anlotinib and cabozantinib needs to be comprehensively considered based on the patient's specific situation, disease progression, gene mutation status, drug indications and side effects, and other factors.

Anlotinib is a multi-target small molecule tyrosine kinase inhibitor that mainly inhibits VEGFR, PDGFR, FGFR, c-Kit and other signaling pathways, and has the effect of inhibiting tumor angiogenesis and tumor growth.

Cabozantinib is also a multi-target tyrosine kinase inhibitor that can inhibit MET, VEGFR, RET and other targets related to tumor growth and metastasis.

Anlotinib is mainly used for locally advanced and metastatic non-small cell lung cancer (NSCLC), including lung squamous cell carcinoma, that has progressed or relapsed after at least two or more systemic chemotherapy treatments. It is clinically contraindicated for patients with central squamous cell carcinoma of the lung or patients at risk of hemoptysis.

Cabozantinib is primarily used in patients with advanced NSCLC rearrangements of RET and as a treatment option in cases of other genetic mutations or failure of conventional treatments.

Both have shown certain efficacy in the treatment of lung cancer, but the specific effects vary depending on individual patients. In terms of safety, both have certain side effects, such as hypertension, hand-foot syndrome, diarrhea, fatigue, etc. However, most side effects are mild to moderate and can be effectively managed with dose adjustment and supportive care.

First of all, it is recommended that lung cancer patients undergo comprehensive genetic testing to determine whether there are specific gene mutations, such as RET rearrangements, EGFRmutations etc. This helps doctors choose more appropriate targeted therapies for patients. Evaluate whether the patient is suitable for anlotinib or cabozantinib based on the patient's disease progression, physical condition, and previous treatment.

If the patient has specific gene mutations such as RET rearrangement and meets the indications for cabozantinib, cabozantinib can be considered. For patients with other types of advanced NSCLC, especially those who have progressed or relapsed after multiple systemic chemotherapy, anlotinib may be a suitable option.